

Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY
Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090



Ref. : NPL/SE/2022

Date : 11th November, 2022

Online filing at www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
MUMBAI - 400001

BSE CODE: 530119

Sub: Submission of the Standalone Un-Audited Financial Results alongwith the Statement of Assets & Liabilities and Cash Flow Statement and Limited Review Report for the Half year/Quarter ended 30th September, 2022 u/r 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir,

This is in continuation of our letter no. NPL/SE/2022 dated 2nd November, 2022 regarding intimation of Board meeting for consideration and approval of the Standalone Un-Audited Financial Results alongwith the Statement of Assets & Liabilities and Cash Flow Statement and Limited Review Report thereon, for the Quarter/Half year ended 30th September, 2022.

Pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015 we are pleased to submit the following;

- Standalone Unaudited Financial Results for the half year/quarter ended 30th September, 2022;
- Standalone Limited Review Report by the Auditors for the half year/quarter ended 30th September, 2022;
- Standalone Statement of Assets & Liabilities for the half year ended 30th September, 2022;
- Standalone Statement of Cash flow for the half year ended 30th September, 2022.

which was considered and approved by the Board at their 4/2022-23 Meeting held on Friday, the 11th November, 2022.

The Financial Results will also be published in widely circulated English and Hindi (Vernacular) newspaper in the prescribed format for that purpose.


We are also in process of filing the aforesaid financial results in the XBRL format within the stipulated time and same shall be hosted on the Website of the Company.

You are requested to please take on record the above said documents for your reference and record.

Thanking You,
Yours Faithfully,

For, NATRAJ PROTEINS LIMITED

Kailash Chand Sharma
Digitally signed by
Kailash Chand Sharma
Date: 2022.11.11
16:22:31 +05'30'



KAILASH CHAND SHARMA
CHAIRMAN & MANAGING DIRECTOR

DIN: 00012900

Enclosed: a/a

NATRAJ PROTEINS LIMITED


CIN: L00153MP1990PLC006090

Regd. Off. -Nagpur Kalan, Ordinance Factory Road, Itarsi, (M.P.)-461111
Ph No. 7974094919

Email: natrajproteinltd@rediffmail.com

Statement of Standalone Un-Audited Financial Results for the quarter and Half-Year ended on 30th Sept., 2022

Part I		(Rs. In Lakhs except EPS)					
Statement of Standalone Unaudited Financial Results for the Quarter/half year Ended 30 th September, 2022							
S. No.	Particulars	Quarter			Half Year		Year
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	6 months ended	Corresponding 6 months ended in the previous year	Previous year ended
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	31/03/2022
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income/Revenue from Operations	3030.51	2233.15	3487.65	5263.66	6326.25	14471.18
II	Other Income	2.41	1.93	2.46	4.34	15.72	26.40
III	Total Income (I+II)	3032.92	2235.08	3490.11	5268.00	6341.97	14497.58
IV	Expenses						
A	Cost of Materials consumed	892.65	880.48	1116.53	1773.13	2404.94	10448.52
B	Purchase of Stock-in-Trade	446.60	1516.16	180.27	1962.76	284.32	1651.89
C	Changes in inventories of finished goods stock-in-trade and work-in-progress	1644.02	(341.73)	1199.52	1302.29	1573.21	220.08
D	Employee benefits expense	24.12	31.75	19.48	55.87	57.39	139.37
E	Finance Costs	22.79	50.47	11.02	73.26	42.28	107.25
F	Depreciation and amortization expense	10.44	10.32	9.88	20.76	19.76	39.60
G	Other expenses	48.48	73.24	88.69	121.72	203.51	595.25
	Total Expenses (IV)	3089.10	2220.69	2625.39	5309.79	4585.41	13201.96
V	Profit/ (Loss) before exceptional items and Tax (I-IV)	(56.18)	14.39	864.72	(41.79)	1756.56	1295.62
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	(56.18)	14.39	864.72	(41.79)	1756.56	1295.62
VIII	Tax expense:						
	(1) Current Tax	(1.32)	1.32	219.82	0.00	421.92	341.68
	(2) Deferred Tax	2.76	3.54	(26.00)	6.30	(3.47)	(13.18)
	(3) Income tax related to earlier years	-	-	-	-	-	4.54
IX	Profit / (Loss) for the period from continuing operations (VII-VIII)	(57.62)	9.53	670.90	(48.09)	1338.11	936.22
X	Profit / (Loss) from Discontinuing operations	-	-	-	-	-	-
XI	Tax expenses of Discontinuing operations	-	-	-	-	-	-
XII	Profit / (Loss) from Discontinuing operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX+XII)	(57.62)	9.53	670.90	(48.09)	1338.11	936.22



XIV	Other Comprehensive Income:						
	A (i) Items that will not be reclassified to Profit or loss	(0.95)	2.83	4.67	1.88	11.64	4.29
	(ii) Income Tax relating to items that will not be reclassified to Profit or loss	-	-	-	-	-	(1.25)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit/(Loss) and other Comprehensive Income for the period)	(58.57)	12.36	675.57	(46.21)	1349.75	939.26
XVI	Paid up Share Capital of the Company (Face Value Rs. 10/-)	374.70	374.70	374.70	374.70	374.70	374.70
XVII	Reserves excluding revaluation reserves	-	-	-	-	-	4171.25
XVIII	Earnings Per Share (for continuing operations)						
	(a) Basic	(1.53)	0.25	17.90	(1.28)	35.71	24.99
	(b) Diluted	(1.53)	0.25	17.90	(1.28)	35.71	24.99
XIX	Earnings Per Share (for Discontinued operations)						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XX	Earnings Per Share (for Discontinued and continuing operations)						
	(a) Basic	(1.53)	0.25	17.90	(1.28)	35.71	24.99
	(b) Diluted	(1.53)	0.25	17.90	(1.28)	35.71	24.99

Note :-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11th November, 2022.
- The above financial results are prepared in compliance with Indian Accounting Standards ("IND-AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015] as amended.
- The company operates in two segments i.e. solvent extraction and commodities derivative trading. However, for the current quarter as well as corresponding quarter in previous year there is no requirement of segmental reporting as the sales of commodities/derivatives are less than the threshold limits.
- The Standalone Statement of Assets and Liabilities as at 30th September, 2022 and the Statement of Cash Flow is provided as an annexure to this statement.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/half year ended on 30th September, 2022. The report does not have any impact on the above results and notes which needs explanation
- Previous period figures have been regrouped/ reclassified wherever necessary to confirm to this period classification.
- Effective from 1st April, 2019, the company has adopted Indian Accounting Standard (IND-AS 116) "Leases" using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1st April, 2022 and there was no material impact on financial results for the quarter ended on 30th September, 2022.



For, NATRAJ PROTEINS LIMITED

KAILASH CHAND SHARMA
Chairman & Managing Director
DIN: 00012900

Date: 11.11.2022
Place: Itarsi

STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS ON 30.09.2022

Statement of Assets and Liabilities		(Rupees in Lakhs)	
Particulars	Note No.	Figures as at the end of current reporting period 30.09.2022	Figures as at the end of previous reporting period 31.03.2022
		Un-Audited	Audited
ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment		412.21	411.86
(b) Capital Work-in-Progress		47.45	-
(c) Investment Property		-	-
(d) Goodwill		-	-
(e) Other Intangible assets		-	-
(f) Intangible assets under development		-	-
(g) Biological Assets other than bearer plants		-	-
(h) Financial Assets			
i. Investments		-	-
ii. Trade receivables		260.56	354.14
iii. Loans		222.55	232.43
iv. Others (to be specified)		-	-
(i) Deferred tax assets (net)		-	-
(j) Other non-current assets		269.11	201.47
Total Non-Current Assets		1211.88	1199.90
(2) Current Assets			
(a) Inventories		1841.47	3990.69
(b) Financial Assets			
i. Investments		59.60	63.68
ii. Trade receivables		1175.82	1721.70
iii. Cash and cash equivalents		2357.36	482.20
iv. Bank balances other than (iii) above		-	-
v. Loans		138.13	40.83
vi. Other (to be specified)		11.21	79.69
(c) Current Tax Assets (Net)		-	-
(d) Other current assets		-	-
Total Current Assets		5583.59	6378.79
Total Assets		6795.47	7578.69
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share Capital		374.70	374.70
(b) Other Equity		4125.04	4171.25
LIABILITIES			
(1) Non-current liabilities			
(a) Financial Liabilities			
(i) Borrowings		426.33	314.17
(ii) Trade payables			
- Total outstanding dues of Micro and small enterprises;			-
- Total outstanding dues of creditors other than Micro and small enterprises;		6.65	6.61
(iii) Other Financial liabilities (other than those specified in item (b), to be specified)		-	-
(b) Provisions			
© Deferred tax liabilities (Net)		-	-
(d) Other non-current liabilities		81.30	75.00
Total Non-Current Liabilities		-	-
(2) Current liabilities			
(a) Financial Liabilities			
(i) Borrowings		1342.35	2409.78
(ii) Trade payables			
- Total outstanding dues of Micro and small enterprises;			
- Total outstanding dues of creditors			



other than Micro and small enterprises;		341.99	99.34
(iii) Other Financial liabilities (other than those specified in item ©)		-	-
(b) Other current liabilities		97.11	77.41
© Provisions		-	-
(d) Current Tax Liabilities (Net)		-	50.43
Total Current Liabilities		1781.45	2636.96
Total Equity and Liabilities		6795.47	7578.69

Date: 11.11.2022
Place: Itarsi



For, NATRAJ PROTEINS LIMITED


KAILASH CHAND SHARMA
Chairman & Managing Director
DIN: 00012900

Standalone Cash Flow Statement for the Year ended 30th Sept., 2022

(Rupees in Lakhs)

	For the Half Year ended 30.09.2022	For the Year ended 31.03.2022
A. CASH FLOW FROM OPERATING ACTIVITIES		
NET PROFIT BEFORE TAXATION AND EXTRAORDINARY ITEM	(41.79)	1295.62
ADJUSTMENT FOR:		
Depreciation and amortization expenses	20.76	39.60
Interest Paid	73.26	107.25
Interest Income	4.34	26.40
Others	-	38.64
Operating Profit before Working Capital Changes	47.89	1377.43
ADJUSTMENTS FOR:		
Trade receivables	545.87	(250.93)
Inventories	2149.22	391.37
loans, advances and other assets	(27.24)	(86.65)
Current liabilities	211.60	(536.46)
CASH GENERATED FROM OPERATIONS		
Income tax paid	2.5	(304.54)
Indirect tax paid	-	-
Total Adjustments	2881.96	(787.21)
NET CASH FROM OPERATING ACTIVITIES	2929.85	590.22
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment, Intangibles etc.	(66.32)	(185.64)
Non-current Assets, Long-term Loans and Advances	4.34	(179.92)
Interest received	35.82	26.40
NET CASH USED IN/ FROM INVESTING ACTIVITIES	(26.17)	(339.16)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long-term borrowings	112.17	314.17
Proceeds from Short-term borrowings/Banks	(1067.43)	-
Interest paid	(73.26)	(107.25)
NET CASH USED IN/ FROM FINANCING ACTIVITIES	(1028.53)	206.92
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	1875.16	457.98
OPENING CASH AND CASH EQUIVALENTS	482.20	24.22
CLOSING CASH AND CASH EQUIVALENTS	2357.36	482.20

For, NATRAJ PROTEINS LIMITED



*KAILASH CHAND SHARMA
Chairman & Managing Director
DIN: 00012900

Date: 11.11.2022
Place: Itarsi



BHUTORIA GANESAN & CO.
CHARTERED ACCOUNTANTS

**Limited Review Report on Un-Audited Standalone Quarter and Half Year ended Financial
Results of the Company**

*(Pursuant to the Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended)*

To,
The Board of Directors of
NATRAJ PROTEINS LIMITED
Itarsi (M.P.)

We have reviewed the accompanying statement of unaudited Standalone financial results of **Natraj Proteins Limited** for the quarter ended 30th September, 2022 and year to date from 1st April, 2022 to 30th September 2022 (the Statement) attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended.

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting standard 34 "Interim Financial Reporting" ("Ind AS-34"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended ("Listing Regulation"). Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhutoria Ganesan & Co
Chartered Accountants
FRN No. 004465C

Place: Bhopal
Date: 11-11-2022

UDIN: 22402792BCVIAU3736

CA R. Gokulkrishnan
Partner
M. No. 402792

